Gene Therapy Breakthrough
New Gene-Editing Treatment Could Offer One-Time Prevention for Heart Disease
A single infusion of an experimental gene-editing treatment cut LDL — or "bad" — cholesterol by up to 62% in patients, and the effects lasted at least 18 months, according to a new study published in The New England Journal of Medicine. The trial involved 35 patients with dangerously high inherited cholesterol or existing heart disease.
Researchers hope the treatment, called VERVE-102, could one day offer a permanent fix for heart disease — the leading cause of death in the U.S., killing around 800,000 people each year. "A curative therapy would change the game," said Dr. John H. P. Alexander, a cardiologist at Duke University, according to The New York Times.
How a Single DNA Tweak Switches Off Bad Cholesterol
VERVE-102 uses a technique called base editing. Think of it as a pencil rather than scissors. Instead of cutting DNA, it makes one tiny letter change — A to G — in a gene called PCSK9 inside liver cells. That gene controls how well the body clears LDL cholesterol from the blood. Switch it off, and LDL drops, according to Pharmacy Times.
At the highest dose tested — 1.0 mg/kg — LDL fell by up to 62% and the protein the PCSK9 gene produces dropped by up to 88%, TCTMD reported. Those results held steady in patients treated 18 months earlier. Alice Thomas, a 64-year-old from North Carolina, saw her LDL fall from 190 to 80 after one infusion, according to The New York Times.
Why Daily Pills Aren't Cutting It for Most Patients
Today, doctors treat high cholesterol with daily statins or twice-monthly injections. But adherence is a huge problem. Between 30% and 50% of patients stop taking their cholesterol drugs within two years, according to research cited by PMC. That gap leaves millions at risk of heart attacks and strokes.
Verve CEO Dr. Sekar Kathiresan, a cardiologist who co-founded the company after his brother died of a sudden cardiac arrest at 42, wants to change that. "We're going for a medicine that someday could be part of primary care," he told The New York Times. A one-time treatment would sidestep the compliance problem entirely.
Safety Concerns and a $1.3 Billion Bet From Eli Lilly
VERVE-102 is the second-generation version of this therapy. An earlier version, VERVE-101, was paused in April 2024 after a patient had liver enzyme problems and low platelet counts, BioSpace reported. So far, VERVE-102 has shown no serious safety issues — but experts urge caution. Dr. J. Michael Gaziano of Boston VA said "we need much more safety data," noting that the FDA requires 15-year follow-up for all gene therapy patients.
Eli Lilly clearly sees the potential. In June 2025, the drugmaker agreed to acquire Verve Therapeutics for up to $1.3 billion, Eli Lilly announced. That move targets a massive market — Amgen's cholesterol drug Repatha alone made $2.2 billion in 2024, according to Cardiovascular Business.
Promising but Early: What Comes Next for VERVE-102
The trial is still small — just 35 patients. Larger studies are needed before the treatment can reach the public. Bioethicists have also raised concerns that a one-time cure, likely priced at a premium, could first reach only wealthy patients, deepening health inequality, according to the Innovative Genomics Institute.
Still, analysts are encouraged. Myles Minter of William Blair said any LDL reduction above 50% with a clean safety record is "the bar you want to be at" — and VERVE-102 cleared it, Fierce Biotech reported. Researchers also hope to eventually expand the treatment beyond rare inherited conditions to the general public as a "vaccine-like" shield against heart disease as people age.
Sentiment
NeutralPublishers
9
Articles
8
Reach
9
